Clinical and genetic analysis of tuberous sclerosis complex‑associated renal angiomyolipoma in Chinese pedigrees

Li,Shuqiang; Zhang,Yushi; Wei,Jinxing; Zhang,Xuepei

doi:10.3892/ol.2017.7079

Clinical and genetic analysis of tuberous sclerosis complex‑associated renal angiomyolipoma in Chinese pedigrees

Authors:
- Shuqiang Li
- Yushi Zhang
- Jinxing Wei
- Xuepei Zhang
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China, Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P.R. China
Published online on: September 27, 2017 https://doi.org/10.3892/ol.2017.7079
Pages: 7085-7090
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tuberous sclerosis complex‑associated renal angiomyolipoma (TSC‑RAML) confers a high risk of bleeding and even mortality. However, data on TSC‑RAML in Chinese pedigrees is extremely lacking. The present study aimed to investigate its clinical and genetic characteristics by obtaining a detailed medical history from 6 probands and their family members, and reassessing blood tests, computed tomography and renal dynamic imaging examinations that were conducted in the TSC‑RAML patients. The TSC1/TSC2 mutation was detected in 2 families. A total of 3 TSC‑RAML patients underwent partial nephrectomy due to a high bleeding risk, and the other 2 were treated with everolimus. The remaining 6 TSC‑RAML patients received no clinical intervention and only had clinical follow‑uzp. It was found that nearly 37% (18/49) were TSC patients, with the mean ± standard deviation diagnostic age being 34.22±17.73 years old in the 6 pedigrees, 61% (11/18) of whom suffered from TSC‑RAML. In the 11 TSC‑RAML patients, the maximum diameter of the tumor ranged between 1.20 and 32.50 cm (mean ± standard deviation, 11.48±8.40 cm), the unilateral glomerular filtration rate ranged between 27.20 and 60.10 ml/min (mean ± standard deviation, 42.55±9.73 ml/min), the serum creatinine level ranged between 40.00 and 90.00 µmol/l (mean ± standard deviation, 64.84±16.15 µmol/l) and the hemoglobin concentration ranged between 76.00 and 140.00 g/l (mean ± standard deviation, 107.73±21.04 g/l). Pathogenic mutations of TSC1 (c.733C>T) and TSC2 (c.788_789insC) were detected in family B and C, respectively, as well as certain non‑pathogenic mutations, with the maximum diameter of TSC‑RAML being 0 cm and 10.3 cm in the two patients from family B and 16 cm and 1.2 cm in the two patients from family C. Expression of phosphorylated‑mechanistic target of rapamycin was determined in the TSC‑RAML tissues by immunohistochemistry. The maximum diameter of the tumor decreased by 4.90 and 5.30 cm, respectively, in the 2 patients treated with everolimus after 3 months. In conclusion, TSC cannot be easily diagnosed due to its variable characteristics. Growth of TSC‑RAML may increase the bleeding risk and reduce the level of hemoglobin, but it does not greatly affect renal function. Individual differences in tumor dimensions existed even with the same pathogenic mutation, except for cases of coexistent non‑pathogenic mutations. Everolimus treatment appears to be able to significantly reduce the size of TSC‑RAML.

View Figures

View References

1	Curatolo P, Bombardieri R and Jozwiak S: Tuberous sclerosis. Lancet. 372:657–668. 2008. View Article : Google Scholar : PubMed/NCBI
2	Krueger DA and Northrup H; International Tuberous Sclerosis Complex Consensus Group, . Tuberous sclerosis complex surveillance and management: Recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol. 49:255–265. 2013. View Article : Google Scholar : PubMed/NCBI
3	Rosser T, Panigrahy A and McClintock W: The diverse clinical manifestations of tuberous sclerosis complex: A review. Semin Pediatr Neurol. 13:27–36. 2006. View Article : Google Scholar : PubMed/NCBI
4	O'Callaghan FJ, Noakes MJ, Martyn CN and Osborne JP: An epidemiological study of renal pathology in tuberous sclerosis complex. BJU Int. 94:853–857. 2004. View Article : Google Scholar : PubMed/NCBI
5	Rakowski SK, Winterkorn EB, Paul E, Steele DJ, Halpern EF and Thiele EA: Renal manifestations of tuberous sclerosis complex: Incidence, prognosis and predictive factors. Kidney Int. 70:1777–1782. 2006. View Article : Google Scholar : PubMed/NCBI
6	Demuth D, Nasuti P, Lucchese L, Gray L, Pinnegar A and Magestro M: Economic impact of patients with tuberous sclerosis complex (tsc) in the Uk: A retrospective database analysis in the clinical practice research datalink (Cprd). Value in Health. 17:A1372014. View Article : Google Scholar
7	Rentz AM, Skalicky AM, Liu Z, Wheless JW, Dunn DW, Frost MD, Nakagawa J, Magestro M and Prestifilippo J: Tuberous sclerosis complex: A survey of health care resource use and health burden. Pediatr Neurol. 52:435–441. 2015. View Article : Google Scholar : PubMed/NCBI
8	Kakkar A, Vallonthaiel AG, Sharma MC, Bora G, Panda A and Seth A: Composite renal cell carcinoma and angiomyolipoma in a patient with Tuberous sclerosis: A diagnostic dilemma. Can Urol Assoc J. 9:E507–E510. 2015. View Article : Google Scholar : PubMed/NCBI
9	Falsafi P, Taghavi-Zenouz A, Khorshidi-Khiyavi R, Nezami N and Estiar MA: A case of tuberous sclerosis without multiorgan involvement. Glob J Health Sci. 7:124–131. 2015. View Article : Google Scholar : PubMed/NCBI
10	Xue G, Han X, Ren S and Yue X: An Analysis of 11 Cases of Tuberous Sclerosis from Three Genealogies. Chin J Neuroimmunol and Neurol. 6:249–252. 1999.
11	Zhang Y, Gan J, Pu Z, Xu Mm, Wang LF, Li YH and Liu ZG: TSC1 R509X mutation in a chinese family with tuberous sclerosis complex. Neuromolecular Med. 17:202–208. 2015. View Article : Google Scholar : PubMed/NCBI
12	Dixon BP, Hulbert JC and Bissler JJ: Tuberous sclerosis complex renal disease. Nephron Exp Nephrol. 118:e15–e20. 2011. View Article : Google Scholar : PubMed/NCBI
13	Northrup H and Krueger DA; International Tuberous Sclerosis Complex Consensus Group, . Tuberous sclerosis complex diagnostic criteria update: Recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol. 49:243–254. 2013. View Article : Google Scholar : PubMed/NCBI
14	Tee AR, Manning BD, Roux PP, Cantley LC and Blenis J: Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol. 13:1259–1268. 2003. View Article : Google Scholar : PubMed/NCBI
15	Wataya-Kaneda M: Mammalian target of rapamycin and tuberous sclerosis complex. J Dermatol Sci. 79:93–100. 2015. View Article : Google Scholar : PubMed/NCBI
16	Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-Kievit A, Zonnenberg B, Verhoef S, Halley D and van den Ouweland A: Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: Genotype--phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet. 13:731–741. 2005. View Article : Google Scholar : PubMed/NCBI
17	Au KS, Williams AT, Roach ES, Batchelor L, Sparagana SP, Delgado MR, Wheless JW, Baumgartner JE, Roa BB, Wilson CM, et al: Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med. 9:88–100. 2007. View Article : Google Scholar : PubMed/NCBI
18	De Waele L, Lagae L and Mekahli D: Tuberous sclerosis complex: The past and the future. Pediatr Nephrol. 30:1771–1780. 2015. View Article : Google Scholar : PubMed/NCBI
19	Seyam RM, Bissada NK, Kattan SA, Mokhtar AA, Aslam M, Fahmy WE, Mourad WA, Binmahfouz AA, Alzahrani HM and Hanash KA: Changing trends in presentation, diagnosis and management of renal angiomyolipoma: Comparison of sporadic and tuberous sclerosis complex-associated forms. Urology. 72:1077–1082. 2008. View Article : Google Scholar : PubMed/NCBI
20	DiMario FJ Jr, Sahin M and Ebrahimi-Fakhari D: Tuberous sclerosis complex. Pediatr Clin North Am. 62:633–648. 2015. View Article : Google Scholar : PubMed/NCBI
21	Ruppe V, Dilsiz P, Reiss CS, Carlson C, Devinsky O, Zagzag D, Weiner HL and Talos DM: Developmental brain abnormalities in tuberous sclerosis complex: A comparative tissue analysis of cortical tubers and perituberal cortex. Epilepsia. 55:539–550. 2014. View Article : Google Scholar : PubMed/NCBI
22	Chan JY, Wang KH, Fang CL and Chen WY: Fibrous papule of the face, similar to tuberous sclerosis complex-associated angiofibroma, shows activation of the mammalian target of rapamycin pathway: Evidence for a novel therapeutic strategy? PLoS One. 9:e894672014. View Article : Google Scholar : PubMed/NCBI
23	Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, et al: Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 381:817–824. 2013. View Article : Google Scholar : PubMed/NCBI
24	Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, et al: Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: Extension of a randomized controlled trial. Nephrol Dial Transplant. 31:111–119. 2015. View Article : Google Scholar : PubMed/NCBI